{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:34:30Z","timestamp":1761568470982,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.3816\/cgc.2009.n.019","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T21:04:30Z","timestamp":1250715870000},"page":"E34-E36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Eosinophilic Rash Secondary to Temsirolimus"],"prefix":"10.3816","volume":"7","author":[{"given":"Mona","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2009.n.019_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0190-9622(94)70120-2","article-title":"Eosinophilic spongiosis: a clinical, histologic, and immunopathologic study","volume":"30","author":"Ruiz","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CGC.2009.n.019_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1358\/dot.2007.43.10.1148059","article-title":"Temsirolimus","volume":"43","author":"Ma","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.3816\/CGC.2009.n.019_bib3","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with Interferon alfa for advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.3816\/CGC.2009.n.019_bib4","first-page":"CD006017","article-title":"Targeted therapy for advanced renal cell Carcinoma","author":"Coppin","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3816\/CGC.2009.n.019_bib5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2009.n.019_bib6","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase 1 and pharmokinetics study of temsirolimus (CCI-779) administered intravenous daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2009.n.019_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitorassociated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"Oncologist"},{"key":"10.3816\/CGC.2009.n.019_bib8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.3816\/CGC.2009.n.019_bib9","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1200\/JCO.2006.08.6868","article-title":"Hand-foot syndrome and seborrheic dermatitis-Like rash induced by sunitinib in a patient with advanced renal cell carcinoma","volume":"24","author":"Tsai","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.019_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature04659","article-title":"A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth","volume":"441","author":"Kim","year":"2006","journal-title":"Nature"},{"key":"10.3816\/CGC.2009.n.019_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/lt.20499","article-title":"Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient","volume":"11","author":"Tracey","year":"2005","journal-title":"Liver Transpl"},{"key":"10.3816\/CGC.2009.n.019_bib12","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.019_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of Sorafenib, sunitinib, and temsirolimus and their management in patients with Metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731170026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731170026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:20:16Z","timestamp":1761564016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731170026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S155876731170026X"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2009.n.019","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilic Rash Secondary to Temsirolimus","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CGC.2009.n.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}